Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
出版年份 2019 全文链接
标题
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-11-14
DOI
10.1186/s40425-019-0787-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab
- (2019) Matthew Scarpelli et al. Journal for ImmunoTherapy of Cancer
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2019) James L. Gulley et al. JOURNAL OF CLINICAL ONCOLOGY
- The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
- (2019) Kalijn F. Bol et al. Journal for ImmunoTherapy of Cancer
- Now the dust has settled over immune checkpoint blockade in metastatic prostate cancer
- (2018) N Mehra et al. ANNALS OF ONCOLOGY
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- (2017) Tomasz M. Beer et al. EUROPEAN UROLOGY
- Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA
- (2017) Mario Eisenberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
- (2016) Steve Boudewijns et al. JOURNAL OF IMMUNOTHERAPY
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- Amplification of MUC1 in prostate cancer metastasis and CRPC development
- (2016) Nicholas Wong et al. Oncotarget
- Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity
- (2016) Jasper J. P. van Beek et al. OncoImmunology
- Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets
- (2015) Annette E. Sköld et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
- (2015) G. Schreibelt et al. CLINICAL CANCER RESEARCH
- A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer
- (2015) Rebecca L. Prue et al. JOURNAL OF IMMUNOTHERAPY
- Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
- (2015) M. Eiber et al. JOURNAL OF NUCLEAR MEDICINE
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients
- (2015) Kalijn F Bol et al. OncoImmunology
- Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy
- (2014) Ghaith Bakdash et al. Expert Review of Clinical Immunology
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
- (2014) Harm Westdorp et al. Frontiers in Immunology
- Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses
- (2013) G. Nizzoli et al. BLOOD
- Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
- (2013) J. Tel et al. CANCER RESEARCH
- Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells
- (2013) E. H. J. G. Aarntzen et al. CLINICAL CANCER RESEARCH
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- Dendritic-Cell-Based Therapeutic Cancer Vaccines
- (2013) Karolina Palucka et al. IMMUNITY
- Challenges of Guarantee-Time Bias
- (2013) Anita Giobbie-Hurder et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of end points for cancer immunotherapy trials
- (2012) A. Hoos ANNALS OF ONCOLOGY
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
- (2012) Nadeem A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma
- (2012) E. H. J. G. Aarntzen et al. CANCER RESEARCH
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer
- (2011) Lotta von Boehmer et al. PLoS One
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation
- (2009) D. Piccioli et al. BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study
- (2008) Roel AM Heesakkers et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started